Cáncer de páncreas

+ -Text Size

Otros recursos y referencias TEMAS

Referencias: guía detallada del cáncer de páncreas

American Cancer Society. Cancer Facts & Figures 2013. Atlanta, Ga: American Cancer Society; 2013.

American Cancer Society. Cancer Facts & Figures 2014. Atlanta, Ga: American Cancer Society; 2014.

American Joint Committee on Cancer. Exocrine and Endocrine Pancreas. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010:241−246.

Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP, Talamonti MS. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007 Aug 15;110(4):738−744.

Bilimoria KY, Bentrem DJ, Merkow RP, Tomlinson JS, Stewart AK, Ko CY, Talamonti MS. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg. 2007 Oct;205(4):558-563.

Caprotti R, Brivio F, Fumagalli L, et al. Free-from-progression period and overall short preoperative immunotherapy with IL-2 increases the survival of pancreatic cancer patients treated with macroscopically radical surgery. Anticancer Res. 2008 May-Jun;28(3B):1951−1954.

Chen J, Li D, Killary AM, et al. Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. Ann Surg Oncol. 2009 Feb;16(2):431−439. Epub 2008 Nov 20.

Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817−1825.

Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009 Nov 20;27(33):5513−5518. Epub 2009 Oct 26.

Debrin JA, Sun W, Metz JM, Furth EE. Carcinoma of the Pancreas. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Kastan MB, McKenna WG, eds. Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008: 1595−1609.

Fjallskog ML, Janson ET, Falkmer UG, et al. Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology. 2008;88(1):53−58.

Freelove R, Walling AD. Pancreatic cancer: diagnosis and management. Am Fam Physician. 2006;73:485−492.

Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010 Apr 20;7(4):e1000267.

Hirooka Y, Itoh A, Kawashima H, et al. A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer. Pancreas. 2009 Apr;38(3):e69−74.

Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.

Kulke MH, Tempero MA, Niedzwiecki D, et al. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009 Nov 20;27(33):5506−5512. Epub 2009 Oct 26.

Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008 May 1;26(13):2124−2130.

Lai G, O'Dorisio T, McDougall R, Weigall RJ. Cancer of the endocrine system. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Kastan MB, McKenna WG, eds. Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008: 1271−1305.

Loehrer PJ Sr, Feng Y, Cardenes H, et al. Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial. J Clin Oncol. 2011 Oct 3. [Epub ahead of print]

Lucenteforte E, La Vecchia C, Silverman D, et al. Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol. 2012 Feb;23(2):374-82. Epub 2011 May 2.

National Cancer Institute. Physician Data Query (PDQ). Pancreatic Cancer: Treatment. 7/17/2012. Accessed at http://www.cancer.gov/cancertopics/pdq/treatment/pancreatic/healthprofessional on November 28, 2012.

National Cancer Institute. Physician Data Query (PDQ). Pancreatic neuroendocrine tumors (islet cell tumors) treatment. 6/29/2012. Accessed at http://www.cancer.gov/cancertopics/pdq/treatment/isletcell/healthprofessional on November 28, 2012.

National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. V.2.2012. Accessed at www.nccn.org on November 28, 2012.

National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology. Neuroendocrine tumors. V.1.2012. Accessed at www.nccn.org on November 29, 2012.

Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010 Sep 8;304(10):1073−1081.

Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007 Jan 17;297(3):267−277.

Online Mendelian Inheritance in Man, OMIM. Lynch syndrome. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD), Available at: http://www.ncbi.nlm.nih.gov/sites/entrez?db=OMIM. Accessed 8/25/2009.

Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10;364(6):501−513.

Roeder F, Timke C, Saleh-Ebrahimi L,et al. Clinical phase I/II trial to investigate neoadjuvant intensity-modulated short term radiation therapy (5 × 5 Gy) and intraoperative radiation therapy (15 Gy) in patients with primarily resectable pancreatic cancer - NEOPANC. BMC Cancer. 2012 Mar 23;12:112.

Royal RE, Wolff RA, Crane CH. Cancer of the Pancreas. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cáncer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011:961−989.

Terashima K, Demizu Y, Hashimoto N, et al. A phase I/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis. Radiother Oncol.2012 Apr;103(1):25-31. Epub 2012 Jan 31.

Wolff RA, Crane CH, Abbruzzese JL, Li D, Evans DB. Neoplasms of the exocrine pancreas. In: Kufe DW, Bast RC, Hait WN, Hong WK, Pollock RE, Weichselbaum RR, Holland JF, Frei E. Cancer Medicine 7. Hamilton, Ontario: BC Decker; 2006:1331−1358.

Wyse JM, Carone M, Paquin SC, Usatii M, Sahai AV. Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer. J Clin Oncol. 2011 Sep 10;29(26):3541-6. Epub 2011 Aug 15.

Yao JC, Rindi G, Evans DB. Pancreatic neuroendocrine tumors. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cáncer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011: 1489−1502.

Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10;364(6):514−523.


Fecha de última actualización: 03/05/2013
Fecha de último cambio o revisión: 02/05/2014